Momenta Pharmaceuticals's revenue for the
three
months ended in Jun. 2020 was $6.61 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2020 was $30.07 Mil.
Momenta Pharmaceuticals's Revenue per Share for the
three
months ended in Jun. 2020 was $0.06.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $0.28.
Warning Sign:
Momenta Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Momenta Pharmaceuticals was -64.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -47.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -20.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -5.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Momenta Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 141.60% per year. The lowest was -47.70% per year. And the median was -1.20% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Momenta Pharmaceuticals's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Momenta Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Momenta Pharmaceuticals's Revenue falls into.
Momenta Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Momenta Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNTA has been successfully added to your 